Angelini Ventures among supporters of $45 million Nuevocor round

Some $45 million has been raised in a Series B financing round by Nuevocor, an investigational new drug (IND)-stage biotech developing therapies for genetic cardiomyopathy, a largely unaddressed condition, by targeting the underlying mechanical defects.

Angelini Ventures co-led the financing with Kurma Partners and participation from Highlight Capital as well as continued significant support from existing investors Boehringer Ingelheim Venture Fund, ClavystBio, EDBI, SEEDS Capital and Xora Innovation.

We’re excited by Nuevocor’s novel approach to treating genetic dilated cardiomyopathy by targeting mechanobiological pathways